Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Status: Recruiting
Location: See all (108) locations...
Study Type: Observational
SUMMARY
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:
• Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
• Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
• Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
Locations
United States
Alabama
Galderma Investigational Site - 8893
ACTIVE_NOT_RECRUITING
Birmingham
Arizona
Galderma Investigational Site - 8535
RECRUITING
Phoenix
Galderma Investigational Site 7060
RECRUITING
Phoenix
Galdrma Investigational Site - 7077
RECRUITING
Phoenix
Galderma Investigational Site - 7067
NOT_YET_RECRUITING
Tucson
California
Galderma Investigational Site - 7074
NOT_YET_RECRUITING
Corona
Galderma Investigational Site 8636
NOT_YET_RECRUITING
Fountain Valley
Galderma Investigational Site 8224
RECRUITING
Fremont
Galderma Investigational Site 7099
NOT_YET_RECRUITING
Los Angeles
Galderma Investigational Site 8553
RECRUITING
Newport Beach
Galderma Investigational Site 7064
NOT_YET_RECRUITING
Santa Monica
Galderma Investigational Site 7107
NOT_YET_RECRUITING
Thousand Oaks
Colorado
Galderma Investigational Site 7061
NOT_YET_RECRUITING
Castle Rock
Connecticut
Galderma Investigational Site 7059
RECRUITING
Fairfield
Florida
Galderma Investigational Site 8597
NOT_YET_RECRUITING
Boca Raton
Galderma Investigational Site 7087
NOT_YET_RECRUITING
Coral Gables
Galderma Investigational Site 7063
RECRUITING
Cutler Bay
Galderma Investigational Site 7134
RECRUITING
Hollywood
Galderma Investigational Site 7101
NOT_YET_RECRUITING
Jupiter
Galderma Investigational Site 7078
RECRUITING
Miami
Galderma Investigational Site 7070
NOT_YET_RECRUITING
North Miami Beach
Galderma Investigational Site 7112
NOT_YET_RECRUITING
Oakland Park
Galderma Investigational Site 7090
RECRUITING
St. Petersburg
Galderma Investigational Site 7054
RECRUITING
Tampa
Illinois
Galderma Investigational Site 7058
RECRUITING
Chicago
Indiana
Galderma Investigational Site 8142
RECRUITING
Indianapolis
Galderma Investigational Site 7083
NOT_YET_RECRUITING
West Lafayette
Massachusetts
Galderma Investigational Site 7065
RECRUITING
Brighton
Galderma Investigationa Site 7104
RECRUITING
Milford
Maryland
Galderma Investigational Site 7098
RECRUITING
Columbia
Galderma Investigational Site 8012
RECRUITING
Glenn Dale
Galderma Investigational Site 7068
RECRUITING
Rockville
Michigan
Galderma Investigational Site 7066
NOT_YET_RECRUITING
Auburn Hills
Galderma Investigational Site 7071
RECRUITING
Caledonia
Galderma Investigational Site 7108
NOT_YET_RECRUITING
Grandville
Galderma Investigational Site 7072
NOT_YET_RECRUITING
Troy
Missouri
Galderma Investigational Site 7057
RECRUITING
Lee's Summit
New Hampshire
Galderma Investigational Site 7055
RECRUITING
Portsmouth
Nevada
Galderma Investigational Site 8848
RECRUITING
Las Vegas
New York
Galderma Investigational Site - Site 7080
RECRUITING
Auburn
Galderma Investigational Site # 7052
RECRUITING
East Syracuse
Galderma Investigational Site - 8282
NOT_YET_RECRUITING
Mount Kisco
Galderma Investigational Site - 7051
RECRUITING
New York
Galderma Investigational Site 7109
RECRUITING
New York
Galderma Investigational Site 8279
NOT_YET_RECRUITING
New York
Ohio
Galderma Investigational Site 7081
RECRUITING
Dayton
Oregon
Galderma Investigational Site 7073
RECRUITING
Gresham
Pennsylvania
Galderma Investigational Site 7103
NOT_YET_RECRUITING
Philadelphia
Galderma Investigational Site 8559
NOT_YET_RECRUITING
Philadelphia
South Carolina
Galderma Investigational Site 7106
NOT_YET_RECRUITING
Bluffton
Texas
Galderma Investigational Site 7082
RECRUITING
Cedar Park
Galderma Investigational Site 8238
RECRUITING
Dallas
Galderma Investigational Site 7062
NOT_YET_RECRUITING
Edinburg
Galderma Investigational Site 7088
RECRUITING
Grapevine
Galderma Investigational Site 7069
RECRUITING
Sugar Land
Galderma Investigational Site 8618
NOT_YET_RECRUITING
Waco
Utah
Galderma Investigational Site 7085
NOT_YET_RECRUITING
Bountiful
Virginia
Galderma Investigational Site 7079
NOT_YET_RECRUITING
Vienna
West Virginia
Galderma Investigational Site 8725
RECRUITING
Morgantown
Other Locations
Germany
Galderma Investigational Site 6387
RECRUITING
Ahaus
Galderma Investigational Site 6383
RECRUITING
Augsburg
Galderma Investigational Site 6416
RECRUITING
Augsburg
Galderma Investigational Site 6366
RECRUITING
Berlin
Galderma Investigational Site 6385
RECRUITING
Berlin
Galderma Investigative Site 6172
RECRUITING
Berlin
Galderma Investigational Site 6398
RECRUITING
Bernau Bei Berlin
Galderma Investigational Site 6386
RECRUITING
Bielefeld
Galderma Investigational Site 6066
RECRUITING
Buxtehude
Galderma Investigational Site 6369
RECRUITING
Erlangen
Galderma Investigational Site 6414
RECRUITING
Gladbeck
Galderma Investigational Site 6418
RECRUITING
Großenhain
Galderma Investigational Site 6370
RECRUITING
Haslach Im Kinzigtal
Galderma Investigational Site 6420
RECRUITING
Hersbruck
Galderma Investigational Site 6374
RECRUITING
Karlsruhe
Galderma Investigational Site 6384
RECRUITING
Koblenz
Galderma Investigational Site 6412
RECRUITING
Langenau
Galderma Investigational Site 6013
RECRUITING
Lübeck
Galderma Investigational Site 6373
RECRUITING
Mainz
Galderma Investigational Site 6371
RECRUITING
Oberursel
Galderma Investigational Site 6411
RECRUITING
Oranienburg
Galderma Investigational Site 6390
RECRUITING
Pforzheim
Galderma Investigational Site 6372
RECRUITING
Quedlinburg
Galderma Investigational Site 6417
RECRUITING
Regensburg
Galderma Investigational Site 6419
RECRUITING
Remscheid
United Kingdom
Galderma Investigational Site 6392
RECRUITING
Birmingham
Galderma Investigational Site 6375
RECRUITING
Bridgend
Galderma Investigational Site 6388
RECRUITING
Epsom
Galderma Investigational Site 5131
RECRUITING
Harrogate
Galderma Investigational Site 6394
RECRUITING
Harrow
Galderma Investigational Site 6400
RECRUITING
Kings Lynn
Galderma Investigational Site 6393
RECRUITING
Kingston Upon Thames
Galderma Investigational Site 6666
NOT_YET_RECRUITING
Kirkcaldy
Galderma Investigational Site 6404
RECRUITING
Leeds
Galderma Investigational Site 6415
RECRUITING
Liverpool
Galderma Investigational Site 5210
RECRUITING
London
Galderma Investigational Site 5408
RECRUITING
London
Galderma Investigational Site 6368
RECRUITING
London
Galderma Investigational Site 6395
RECRUITING
London
Galderma Investigational Site 6396
RECRUITING
Manchester
Galderma Investigational Site 6402
RECRUITING
Metropolitan Borough Of Wirral
Galderma Investigational Site 5431
RECRUITING
Redhill
Galderma Investigational Site 6403
RECRUITING
Sandbach
Galderma Investigational Site 6389
RECRUITING
Sheffield
Galderma Investigational Site 6401
RECRUITING
Southampton
Galderma Investigational Site 5989
RECRUITING
Swansea
Galderma Investigational Site 6399
RECRUITING
Watford
Galderma Investigational Site 5944
RECRUITING
Wolverhampton
Galderma Investigational Site 6397
RECRUITING
York
Contact Information
Primary
Galderma Research and Development
clinical.studies@galderma.com
817-961-5000
Time Frame
Start Date: 2025-07-14
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 1000
Treatments
Nemolizumab
Participants with moderate-to-severe AD who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.
Related Therapeutic Areas
Sponsors
Leads: Galderma R&D